VC-backed arGEN-X raises €40m in IPO
Dutch VC-backed biotech arGEN-X has raised €40m from its IPO of new shares, giving it a market cap of €131.7m.
More on Benelux
Holland Capital backs Dimensys
GP intends to boost the company's growth and consolidate its market position in the Benelux and DACH regions
Forbion et al. in $196m round for NewAmsterdam Pharma
Company intends to use the fresh capital to finance the full phase-III development of its obicetrapib drug
LSP launches €150m fund dedicated to dementia treatment
Vehicle invests in companies that are developing drugs for neurodegenerative diseases
Holland Capital invests in Intercept
Company will use the capital injection to scale up its product development and expand internationally
Latest News
Fidelium Partners acquires RET
Parent company Reiff Group said in a statement that the sale is part of its ongoing realignment plan
Star Capital acquires Rail Operations
Neil Bennett, previously of Beacon Rail Leasing, will be appointed executive chairman of the company
Heal Capital closes debut fund on €100m
Healthtech-focused VC sees oppprtunities in the developing European market, managing director Christian Weiß tells Unquote
Mobeus invests in Northern Bloc
Paul Keen, previously CFO of ETC Venues, will join the board as a non-executive director